Become a member to receive our newsletter and get unrestricted access to downloadable slidekits...
A confirmation email has been sent to
Please click on the Activation Link to activate your account.
If you don't receive our email, please check your spam folder.
Already registered?
Neved registered?
Forgot your codes?
This study enrolled 107 obese, hypertriglyceridaemic subjects treated with atorvastatin, with or without type 2 diabetes. These individuals were randomly allocated to PF-05231023 or placebo intravenously once-weekly for 4 weeks. At day 25, PF-05231023 treatment was associated with reduction in plasma triglycerides (by 33-43%) and an increase in high-density lipoprotein cholesterol concentration (by 15-28%), without significant changes in body weight. However, treatment was also associated with dose-related increases in blood pressure and heart rate. These results call into question the potential of this therapeutic approach for managing elevated triglycerides associated with obesity.